Sanofi (NASDAQ:SNY) Receives Average Recommendation of “Moderate Buy” from Brokerages

Sanofi (NASDAQ:SNY) has been assigned an average recommendation of “Moderate Buy” from the four brokerages that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $57.50.

Several equities research analysts have recently weighed in on the stock. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th.

Sanofi Trading Up 0.9 %

NASDAQ:SNY opened at $48.72 on Thursday. The company has a market capitalization of $123.64 billion, a PE ratio of 24.86, a P/E/G ratio of 1.22 and a beta of 0.61. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97. The stock’s 50 day moving average price is $53.17 and its 200 day moving average price is $52.15. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same period last year, the firm posted $2.55 earnings per share. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. On average, research analysts anticipate that Sanofi will post 4.29 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Northwest Investment Counselors LLC purchased a new stake in shares of Sanofi during the 3rd quarter worth $29,000. POM Investment Strategies LLC purchased a new position in Sanofi in the second quarter valued at about $25,000. Concord Wealth Partners lifted its position in shares of Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after acquiring an additional 363 shares during the period. Arrow Financial Corp purchased a new stake in shares of Sanofi during the 2nd quarter worth approximately $35,000. Finally, Sunbelt Securities Inc. grew its holdings in shares of Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after acquiring an additional 313 shares during the period. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.